Login to Your Account



Paion Raises Investor Hopes On Revival of Desmoteplase

By Cormac Sheridan


Wednesday, October 24, 2007
Paion AG gave its beleaguered investors a little autumnal cheer by raising hopes that its clot-busting stroke drug Desmoteplase might return to the clinic, despite a Phase III clinical trial miss earlier this year that precipitated a share price plunge. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription